Genzyme, BioMarin Drug OKd in Europe

Genzyme Corp. and BioMarin Pharmaceutical Inc. won European approval of their Aldurazyme treatment for a rare genetic disorder.

The European Commission cleared Aldurazyme for sale in the 15 countries of the European Union to treat patients with the enzyme deficiency called MPS1, the companies said. Aldurazyme won U.S. approval in April.